Vertex Pharmaceuticals Incorporated
CorpDigest
Vertex Pharmaceuticals Incorporated
Company History
Founded 1989 in Boston, Massachusetts
Last reviewed: 2026-06-08 · By Swet Parvadiya
The modern corporate entity was founded in 1989 by Dr. Joshua Boger, a former Merck research scientist who pioneered the application of structure-based drug design, but the true strategic inflection point occurred in the late 1990s when the company bet its entire existence on the hypothesis that small molecules could correct the function of the misfolded CFTR protein. In the gene therapy space, the company faces intense competition from established players like bluebird bio, which has launched Zynteglo and Skysona for beta thalassemia and cerebral adrenoleukodystrophy, and from a new wave of allogeneic cell therapy companies that are attempting to eliminate the complex autologous manufacturing process. The origin of Vertex Pharmaceuticals Incorporated is not a single founding moment but a complex evolution of scientific discovery, entrepreneurial ambition, and the brutal economics of the global biopharmaceutical market. The story begins in 1989 when Dr. Joshua Boger, a former research scientist at Merck & Co. founded the company in Cambridge, Massachusetts, with a revolutionary vision: to apply the principles of structure-based drug design to discover novel therapeutics for serious diseases.
Dr. Joshua Boger is an American scientist and entrepreneur who founded Vertex Pharmaceuticals in 1989 and served as its CEO until 1999. He played a pivotal role in the company's early survival, navigating the severe cash crunch of the mid-1990s and executing the strategic pivot to cystic fibrosis that saved the company from bankruptcy. Boger's background as a research scientist at Merck gave him a unique perspective on the pharmaceutical industry, driving his focus on developing therapies for serious diseases using rational, structure-based drug design. During his tenure, he oversaw the early development of the company's HIV protease inhibitor programs and laid the foundational scientific infrastructure that would eventually lead to the discovery of the CFTR modulators. After stepping down as CEO, Boger remained active in the biotechnology community, serving on the boards of several major pharmaceutical companies and continuing to invest in early-stage life science startups. He is widely respected in the industry for his role in creating a global biopharmaceutical powerhouse and for his commitment to bringing novel, life-saving therapies to patients with limited treatment options.
Dr. Joshua Boger founded Vertex Pharmaceuticals in Cambridge, Massachusetts, with an initial focus on applying structure-based drug design to discover novel therapeutics.
Vertex Pharmaceuticals executed its IPO, raising capital to continue operations and advance its early-stage pipeline programs after facing a severe cash crunch.
Vertex entered into a landmark partnership with the Cystic Fibrosis Foundation, betting the company's future on the hypothesis that small molecules could correct the misfolded CFTR protein.
The FDA approved Kalydeco (ivacaftor), the first CFTR potentiator, marking the beginning of Vertex's ascent to the top of the global rare disease hierarchy.
Vertex received FDA approval for Orkambi, the first CFTR modulator combination therapy for patients with the F508del mutation, the most common cause of cystic fibrosis.
The FDA approved Trikafta (elexacaftor/tezacaftor/ivacaftor), a triple-combination therapy that transformed the treatment paradigm for 90% of the CF population.
Vertex acquired ViaCyte for $320 million, securing foundational stem cell technology for the VX-880 type 1 diabetes program.
The FDA approved Casgevy (exa-cel), the first CRISPR-Cas9 gene-edited therapy, co-developed with CRISPR Therapeutics, for sickle cell disease and transfusion-dependent beta thalassemia.
Vertex acquired Alpine Immune Sciences for $4.9 billion, securing the proprietary PTP115 asset for APOL1-mediated kidney disease.
Vertex reported $10.67 billion in net product revenue for FY2024, with operating income reaching $4.6 billion and free cash flow at $3.5 billion, demonstrating strong performance and robust pipeline execution.
Vertex acquired Alpine Immune Sciences for $4.9 billion to gain control of the proprietary PTP115 asset, an oral inhibitor of APOL1 for the treatment of APOL1-mediated kidney disease.
Vertex acquired ViaCyte for $320 million to secure foundational stem cell technology for the VX-880 investigational stem cell-derived islet cell replacement therapy for type 1 diabetes.
Vertex acquired Semma Therapeutics for $950 million to gain control of its stem cell-derived islet cell technology for the treatment of type 1 diabetes.
Vertex Pharmaceuticals was founded in 1989 by Dr. Joshua Boger, a chemist who had been senior director of basic chemistry at Merck Research Laboratories, where he had been a key figure in establishing structure-based rational drug design. Frustrated by Merck's pace and convinced computational chemistry plus protein crystallography could systematically design selective inhibitors of disease-target proteins, Boger left in 1989 to start his own company in Cambridge, Massachusetts, raising initial venture capital from firms including Burr, Egan, Deleage. The early thesis — design drugs by visualizing the three-dimensional binding pocket of a target protein and computationally fitting candidate molecules — was almost heretical at the time, when industry favored random high-throughput screening. Vertex completed an initial public offering on July 24, 1991 at $14 per share, raising roughly $43 million, even though it had no product on the market. The first decade was spent assembling structural-biology platforms and partnerships, including high-profile deals with Eli Lilly, Glaxo Wellcome, Aventis, Novartis and others that funded operations and produced early HIV protease and HCV protease inhibitors before the company transitioned into its modern cystic fibrosis franchise.
Vertex's first major commercial product was telaprevir, an oral protease inhibitor for hepatitis C virus marketed as Incivek in the United States and Incivo elsewhere, approved by the FDA on May 23, 2011. Incivek launched into one of the fastest drug launches in history, reaching $951 million in its first six months and over $1.5 billion in 2012. But the franchise collapsed almost as quickly when Gilead Sciences launched Sovaldi (sofosbuvir) in December 2013, a far better tolerated all-oral regimen that essentially eliminated interferon-based therapies; Vertex effectively exited HCV by mid-2014. Anticipating this, Vertex had been quietly building a cystic fibrosis program based on small-molecule CFTR modulators discovered through a partnership with the Cystic Fibrosis Foundation beginning in 1998. Kalydeco (ivacaftor), the first CFTR potentiator, was approved January 31, 2012 for a tiny G551D mutation population. The CF strategy expanded with Orkambi (lumacaftor/ivacaftor) in 2015, Symdeko (tezacaftor/ivacaftor) in 2018, and finally Trikafta (elexacaftor/tezacaftor/ivacaftor) on October 21, 2019, which addresses roughly 90% of CF patients and transformed Vertex into a profitable, single-disease franchise leader.
Vertex's cystic fibrosis franchise was made possible by an unusual venture-philanthropy partnership with the Cystic Fibrosis Foundation (CFF). Beginning in 1998 and expanded in 2004, CFF — through its venture arm CFF Therapeutics — committed roughly $150 million in funding to Vertex's CFTR modulator program in exchange for royalty rights on resulting drugs. That money allowed Vertex to pursue a then-unfashionable rare-disease target. When Kalydeco was approved in 2012, CFF began collecting royalties, and in November 2014 the foundation sold its royalty rights to Royalty Pharma for $3.3 billion in cash — at the time the largest single payout for a non-profit medical research charity ever. CFF used the proceeds to fund additional research, including gene therapy and the rare CFTR mutations not addressed by Trikafta. The partnership has been cited as a model for venture philanthropy in rare disease and has more recently been the subject of debate over drug pricing — Trikafta carries a U.S. list price north of $300,000 per patient per year — and over royalties owed back to charitable foundations from successful products.
Trikafta (elexacaftor/tezacaftor/ivacaftor) was approved by the FDA on October 21, 2019, five months ahead of its PDUFA date, after Phase III trials showed a roughly 14 percentage-point improvement in ppFEV1 lung function over baseline in patients with at least one F508del mutation, the most common CF genotype. Because F508del is present in roughly 90% of the CF population, Trikafta vastly expanded the addressable patient pool relative to earlier Kalydeco, Orkambi and Symdeko regimens. Sales scaled from $420 million in the partial Q4 2019 launch quarter to $3.9 billion in 2020, $5.7 billion in 2021, $7.7 billion in 2022 and roughly $8.9 billion in 2023 — making Trikafta one of the most successful rare-disease drug launches in pharmaceutical history. The drug has driven Vertex's revenue past $10 billion, generated industry-leading operating margins above 50%, and funded the company's diversification into sickle cell disease, beta-thalassemia, acute pain, type 1 diabetes, and APOL1-mediated kidney disease. Trikafta's composition-of-matter patents extend into the mid-2030s, but Vertex has already begun launching its next-generation triple, Alyftrek, as the successor.
Casgevy (exagamglogene autotemcel, exa-cel) was approved by the FDA on December 8, 2023 for sickle cell disease and on January 16, 2024 for transfusion-dependent beta-thalassemia, making it the first CRISPR/Cas9 gene-edited therapy authorized in the United States. Casgevy is co-developed and co-commercialized with CRISPR Therapeutics under a 2015 collaboration restructured in 2021 so Vertex took a 60% economic share. Pricing was set at $2.2 million per patient in the U.S., placing it among the most expensive medicines ever launched. Treatment requires harvesting a patient's hematopoietic stem cells, editing them ex vivo with CRISPR/Cas9, and re-infusing after myeloablative conditioning — a process that limits initial throughput to a handful of authorized treatment centers. Separately, on December 20, 2024, the FDA approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), Vertex's next-generation triple combination for cystic fibrosis with once-daily dosing and improved sweat-chloride reduction relative to Trikafta. Together with Journavx (suzetrigine), the first FDA-approved selective Nav1.8 sodium channel inhibitor for moderate to severe acute pain — approved January 30, 2025 — these launches mark Vertex's transition from a cystic fibrosis monoline to a multi-franchise biopharmaceutical company.